Abstract: As antibody-drug conjugates (ADCs) grow more complex, comprehensive analytical services are becoming central to successful development from discovery through commercialization.

Abstract: Successful ADC development depends on an analytical strategy that addresses molecular complexity from the earliest stages and evolves through commercialization.

Abstract: For decades, biologics stability programs followed a predictable playbook: generate data, support regulatory filings, satisfy agencies, and move on.

Abstract: Catalent's biologics analytical services are designed to deliver comprehensive support for a diverse range of biologic modalities, including antibodies, conjugates, peptides, nucleic acids, and cell and gene therapies.

Catalent has expanded its industry‑leading GPEx® Lightning platform to include HEK cell line development, creating a new standard for speed, expression control, and product quality in human-cell–based manufacturing.

Summary: This poster presents a customized mass spectrometry approach for sub-ppm quantitation of high-risk host cell proteins (HCPs) considered critical quality attributes.

Summary: This presentation introduces a systematic, data-driven approach for assessing the developability of biologic therapeutics, with a focus on pre-formulation development.

Summary: Catalent’s Bio Early Phase Success Package delivers an integrated analytical strategy designed to de-risk biologics development from discovery through IND.

Summary: This presentation introduces a systematic, data-driven approach for assessing the developability of biologic therapeutics, with a focus on pre-formulation development.

Summary: Characterizing molecular stability early is critical to advancing biologics through development and into the clinic.